Atlas Trials

Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)

Clinical trial NCT07011654 · RECRUITING

Trial details

NCT number
NCT07011654
Sponsor
M.D. Anderson Cancer Center
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Metastatic Triple-Negative Breast Cancer
Start date
2025-09-19
Primary completion
2028-07-01
Enrollment
31

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.